Research programme: brain injury therapies - Edge Therapeutics

Drug Profile

Research programme: brain injury therapies - Edge Therapeutics

Alternative Names: EG-1960; EG-1961; EG-1964; NimoGel™

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Edge Therapeutics
  • Developer Edge Therapeutics; University of Toronto
  • Class Dihydropyridines; Nicotinic-acids
  • Mechanism of Action Calcium channel antagonists; Chymotrypsin inhibitors; Kallikrein inhibitors; Plasmin inhibitors; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cerebral ischaemia; Subdural haematoma
  • Research Brain injuries; Neurological disorders

Most Recent Events

  • 09 Sep 2016 Early research in Neurological disorders in USA before September 2016 (Edge Therapeutics, September 2016)
  • 18 Nov 2014 Edge Therapeutics enters into a collaboration with St. Michael's Hospital, an affiliate of the University of Toronto, to discover therapeutics for the treatment of a variety of acute neurological conditions resulting from neurovascular instability
  • 08 Sep 2014 Edge Therapeutics selects EG 1964 as the second product candidate for the prophylactic treatment of chronic subdural haematoma to prevent recurrent bleeding on the brain surface
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top